International Congress on the Future of Breast Cancer West | Conference

Dr. Pegram on Considerations for Treatment Selection in HER2+ Breast Cancer

August 4th 2021

Mark D. Pegram, MD, discusses considerations for treatment selection in HER2-positive breast cancer.

CDK4/6 Inhibitors Improve OS, but Sequencing Strategies Continue to Form in HR+/HER2- Breast Cancer

August 2nd 2021

Sara A. Hurvitz, MD, highlights that although differences in overall survival and toxicity profile could inform treatment selection with CDK4/6 inhibitors, optimal sequencing with these agents remains uncertain.

Pegram Points to Progress, Ongoing Efforts in Advanced HER2+ Breast Cancer

August 2nd 2021

Physicians treating patients with HER2-positive metastatic breast cancer have had their share of wins with treatment advances in the past few years.

CDK4/6 Inhibitors Continue to Build Traction in Early-Stage ER+/HER2- Breast Cancer

July 30th 2021

Neoadjuvant and adjuvant treatment with CDK4/6 inhibitors has shown encouraging preliminary evidence in patients with estrogen receptor–positive, HER2-negative breast cancer, but confirmation of durable benefit is needed in the adjuvant setting before they are brought into routine clinical practice.

New Focus Needed on Preventing Brain Metastases in Early Breast Cancer

August 1st 2020

Although strategies for treating brain metastases in patients with advanced breast cancer are showing signs of efficacy, new approaches are needed to prevent high-risk, HER2-positive early disease from spreading to the central nervous system.

Sparano Shares Progress Made in the Molecular Guided Management of Breast Cancer

July 31st 2020

The advent of gene expression assays has provided predictive insight into chemotherapy benefit that can be combined with prognostic information yielded by gene expression profiling to better target patients with breast cancer who are at higher clinical risk for the use of adjuvant chemotherapy.

Deciphering DNA Repair Deficiency in Breast Cancer

July 31st 2020

Joyce A. O'Shaughnessy, MD, discusses the importance of research regarding the application of DNA repair deficiency in breast cancer, even though it's still in early stages.

Dr. O’Regan on Biomarkers of Response to CDK4/6 Inhibitors in Breast Cancer

July 31st 2020

Ruth O’Regan, MD, discusses biomarkers of response to CDK4/6 inhibitors in breast cancer.

Dr. Tripathy on Genomically Guided Therapy in Breast Cancer

July 31st 2020

Debu Tripathy, MD, discusses genomically guided therapy in breast cancer.

Dr. Goldstein on Mechanisms of Resistance to Endocrine Therapy

July 19th 2014

Lori Goldstein, MD, director, The Naomi and Phil Lippincott Breast Evaluation Center, deputy associate director, Clinical Research, Fox Chase Cancer Center, discusses mechanisms of resistance to endocrine therapy.

Dr. Tripathy on Decision-Making for Sequencing Therapies for HER2-Positive MBC

July 18th 2014

Debu Tripathy, MD, discusses a decision-making framework for sequencing therapies for HER2-positive metastatic breast cancer.

Dr. O'Shaughnessy on Breast Cancer Subtype-Specific Cytotoxic Agents

July 17th 2014

Joyce A. O'Shaughnessy, MD, discusses the evolving area of breast cancer subtype-specific cytotoxic agents.